CTOs on the Move


 
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.imv-inc.com
  • 130 Eileen Stubbs Ave
    Dartmouth, NS CAN B3B 2C4
  • Phone: 902.492.1819

Executives

Name Title Contact Details

Funding

IMV raised $29.5M on 03/11/2019
IMV raised $25.1M on 05/18/2020

Similar Companies

Pulmatrix Inc

Pulmatrix Inc is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alucent Biomedical

Alucent Biomedical, Inc. is a privately held biotechnology company headquartered in Salt Lake City, Utah and is the first company to bring a novel, locally delivered biotechnology treatment to a market traditionally dominated by medical device solutions. Alucent was founded by Avera Health to develop and market Natural Vascular Scaffolding (NVS). NVS is a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining arterial patency.

Neoleukin

Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.

GenVault Corporation

GenVault Corporation is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xcell Biosciences

Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell`s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing.